Elanco Animal Health Incorporated Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase
Elanco Animal Health Incorporated (ELAN) had Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase of 3.10% as of 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Defined Benefit Plan
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease · last filed 2021-03-01
- 2020-12-31: Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 3.10%.
- 2019-12-31: Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 2.30%.
- 2018-12-31: Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 2.20%.
- 2017-12-31: Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 2.10%.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase |
|---|---|
| 2020-12-31 | 3.10% 10-K · filed 2021-03-01 |
| 2019-12-31 | 2.30% 10-K · filed 2021-03-01 |
| 2018-12-31 | 2.20% 10-K · filed 2021-03-01 |
| 2017-12-31 | 2.10% 10-K · filed 2020-02-28 |
| 2016-12-31 | 3.10% 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |